Ligand Pharmaceuticals Incorporated (LGND) Q2 2015 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.52%

Ligand Pharmaceuticals reported a strong earnings per share, beating expectations by nearly 20%. However, the lack of revenue figures and guidance may leave investors cautious. The stock reacted positively, rising slightly by 0.52%, reflecting investor approval of the EPS surprise.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.81	N/A	+19.87%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook on earnings performance while remaining non-committal about future revenue expectations.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing projects but did not offer specific guidance for the future.

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.52%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.52%

Key numbers

Management commentary